Pulmonary Embolism - Pipeline Review, H2 2016

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pulmonary Embolism Overview 6
Therapeutics Development 7
Pipeline Products for Pulmonary Embolism - Overview 7
Pipeline Products for Pulmonary Embolism - Comparative Analysis 8
Pulmonary Embolism - Therapeutics under Development by Companies 9
Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes 10
Pulmonary Embolism - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Pulmonary Embolism - Products under Development by Companies 13
Pulmonary Embolism - Products under Investigation by Universities/Institutes 14
Pulmonary Embolism - Companies Involved in Therapeutics Development 15
Accu-Break Pharmaceuticals, Inc. 15
Dong-A Socio Holdings Co. Ltd. 16
F. Hoffmann-La Roche Ltd. 17
Genentech, Inc. 18
Pulmonary Embolism - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
STP-023725 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
tenecteplase - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
TMS-007 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TRX-1 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
warfarin potassium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Pulmonary Embolism - Dormant Projects 34
Pulmonary Embolism - Discontinued Products 35
Pulmonary Embolism - Product Development Milestones 36
Featured News & Press Releases 36
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 36
Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 36
Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 37
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 38
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 38
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 40
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 40
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 42
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 42
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 44
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 44
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention 45
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 46
Dec 03, 2013: New Data to be Presented on Bayer's Xarelto Single-Drug Solution for the Treatment and Prevention of Recurrent Pulmonary Embolism and Deep Vein Thrombosis 47
Sep 20, 2013: Pooled Analysis Confirms XARELTO has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE 47
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for Pulmonary Embolism, H2 2016 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals, Inc., H2 2016 15
Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 16
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 17
Pulmonary Embolism - Pipeline by Genentech, Inc., H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Pulmonary Embolism - Dormant Projects, H2 2016 34
Pulmonary Embolism - Discontinued Products, H2 2016 35 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy